The world of celiac disease research changes and evolves each and every day. Beyond Celiac keeps the community up-to-date on research in many ways, including our Research News Feed and the Research Opt-In.
Recently, a group of researchers published their recommendations for standardizing celiac disease clinical trials. While on the whole we agree with the content, we were dismayed to learn that no patients or patient organizations had been consulted to develop these guidelines. We are proud to say that our response, a letter to the editor, was recently published in Gastroenterology.
If a child at risk for celiac disease is prescribed antibiotics multiple times, it may increase the chance that celiac disease will develop, according to a new study. Antibiotics were tied to an increase in a protein that loosens the connection between cells in the intestine. In the future, tests for that protein might be used to determine who is likely to develop celiac disease.
A higher income, living in an urban area and living close to a celiac disease center are all positively correlated with celiac disease prevalence, while being Black or Latino/Hispanic is negatively correlated, according to our research poster presented at Digestive Disease Week 2023.
A recent study found that children who had detectable gluten in urine and stool samples did not have symptoms, backing up earlier evidence that symptoms are not reliable indicators of gluten getting into the gluten-free diet.
Researchers around the world are working to develop new treatments for celiac disease. As a person affected by celiac disease, you can play an important role in advancing research by participating inclinical trials. View our Clinical Trials Infographic to learn how clinical trials tie into to drug development process.
Additionally, Beyond Celiac has been directly involved with assisting a number of clinical studies in all phases. With the largest celiac disease social community, a robust email and research database and a website that receives over 2 million visits a year, we are uniquely qualified to help your clinical trial recruit qualified candidates. Learn about our patient recruitment offerings.
Our Chief Scientific Officers lead the development and implementation of a transformational patient-centered research agenda focused on accelerating solutions toward new pharmaceutical treatments and a cure for celiac disease.
Our Chief Scientist and Strategy Officer develops our research and funding priorities to impact patients in areas including clinical decision-making about disease management, treatment, and eventually a cure.